ReviewHematology. American Society of Hematology. Education Program2018
Richter transformation in the era of novel agents.
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.Nature medicine · 2024Trial
- Trial
- Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases.MedComm · 2026Review
- From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor.European journal of case reports in internal medicine · 2026Article
- Richter's transformation: status quo and quo vadis.Annals of hematology · 2025Review
- Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.Haematologica · 2025Article
- Venetoclax Plus Intensified Chemoimmunotherapy as a Bridge to Allogeneic Stem Cell Transplantation in Richter Syndrome: Report of Two Cases.Hematology reports · 2024Article
- Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2024Article
- Case report: HSV lymphadenitis in immunocompromised patient with CLL.Frontiers in oncology · 2024Article
- Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Fluorodeoxyglucose positron emission tomography (FDG/PET) shows the effect of carbon-ion radiotherapy (CIRT); with pathologic confirmation.Radiology case reports · 2023Article
- Chronic lymphocytic leukaemia/small lymphocytic lymphoma and mantle cell lymphoma: from early lesions to transformation.Virchows Archiv : an international journal of pathology · 2023Review
- [Clonality relatedness and molecular characteristics of Richter transformation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature.Clinical case reports · 2022Article
- Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.Nature medicine · 2022Article
- An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.Journal of the advanced practitioner in oncology · 2022Article
- Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.Cancer genetics · 2022Article
- The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review.Frontiers in oncology · 2022Review
- Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.Blood advances · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.